4. Special Classes of Cancer Therapies

Only available as part of a package

Outline:

  • Risk Evaluation and Mitigation Strategies (REMS)
  • Immunomodulatory Drugs (IMiDs)
  • Proteasome Inhibitors (PIs)
  • Lymphocyte Activation Gene 3 (LAG-3) 
  • Additional Antineoplastic Agentss

After completing this educational activity, participants should be able to:

  • Describe the REMS program and how it applies to select cancer therapies
  • Identify the unique prescribing considerations of immunomodulary drugs, proteosome inhibitors, arsenic trioxide, and tretinoin
  • Recognize key toxicities and black box warnings of the cancer therapies included in this module

Kirollos Hanna

PharmD, BCPS, BCOP

M Health Fairview and Mayo Clinic College of Medicine

Dr. Hanna is board certified in Oncology Pharmacy and Pharmacotherapy. He is an Assistant Professor of Pharmacy at the Mayo Clinic College of Medicine and the Oncology Pharmacy Manager at M Health Fairview, Maple Grove, Minnesota. Dr. Hanna serves as an Associate Editor for JADPRO (Journal of the Advanced Practitioner in Oncology). His research interests focus on B-cell malignancies and genitourinary cancers, and he has published over a dozen peer-reviewed manuscripts in various journals. Dr. Hanna serves on the Executive Council of the National Community Oncology Dispensing Association (NCODA). He has been awarded the 2018 "40 Under 40 in Cancer" by The Lynx Group, Upstream Partners, Swim Across America, and NCODA; the "Next Generation 2019 Specialty Pharmacist" by PharmacyTimes and Parata Systems; and the 2020 " New Practitioner Award" by HOPA.

Kirollos Hanna has the following relevant financial relationships to disclose:

  • Speakers bureau: AbbVie, Astellas, Beigene, Bristol Myers Squibb, Exelixis, PCYC, Seagen
  • Consultant: AbbVie, Seagen

Key:

Complete
Failed
Available
Locked
Risk Evaluation and Mitigation Strategy (REMS) (22 min.)
Open to view video.
Open to view video.
You must register to access.
Risk Evaluation and Mitigation Strategy (REMS) - Knowledge Check
1 Question  |  Unlimited attempts  |  0/1 points to pass
1 Question  |  Unlimited attempts  |  0/1 points to pass Knowledge Check grades DO NOT COUNT towards earning your CE certificate. You will be informed that you passed this quiz once it has been completed.
You must register to access.
Proteasome Inhibitors (PIs) (8 min.)
Open to view video.
Open to view video.
You must register to access.
Proteasome Inhibitors (PIs) - Knowledge Check
3 Questions  |  Unlimited attempts  |  0/3 points to pass
3 Questions  |  Unlimited attempts  |  0/3 points to pass Knowledge Check grades DO NOT COUNT towards earning your CE certificate. You will be informed that you passed this quiz once it has been completed.
You must register to access.
Additional Antineoplastic Agents (11 min.)
Open to view video.
Open to view video.
You must register to access.
Additional Antineoplastic Agents - Knowledge Check
1 Question  |  Unlimited attempts  |  0/1 points to pass
1 Question  |  Unlimited attempts  |  0/1 points to pass Knowledge Check grades DO NOT COUNT towards earning your CE certificate. You will be informed that you passed this quiz once it has been completed.
You must register to access.
Clinical Pearls (6 min.)
Open to view video.
Open to view video.
You must register to access.
Special Classes of Cancer Therapies - Post Test
7 Questions  |  3 attempts  |  5/7 points to pass
7 Questions  |  3 attempts  |  5/7 points to pass This Post Test counts towards your CE Certificate. You must answer at least 5 of 7 questions correctly to earn credit for this module. You have 3 attempts to pass the Post Test.
You must register to access.